FiercePharmaOriginal article
{"a":[{"_":"Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chaper","$":{"href":"/pharma/sarepta-taps-abbvie-tessera-vet-severino-write-duchenne-firms-next-chaper","hreflang":"en"}}]}
Neutral
AI Analysis
Summary
Sarepta Therapeutics announced the appointment of a new permanent CEO to replace retiring longtime chief Doug Ingram, with the new leader coming from AbbVie and Tessera backgrounds.
Importance:3/10
Sentiment:
0.10
management_changeCEO_appointmentleadership
Read the original article
Published by FiercePharma on July 27, 2026 11:21 AM
